mIRV

BIOLOGICAL2 trials

Sponsors

Pfizer, Eli Lilly and Company

Conditions

Fallopian Tube NeoplasmsInfluenza, HumanNeoplasm MetastasisOvarian NeoplasmsPeritoneal Neoplasms

Phase 1

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Modified RNA Vaccine Against Influenza

CompletedNCT05052697

PfizerInfluenza, Human

Start: 2021-09-13End: 2023-01-27Updated: 2024-03-12

Phase 3

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

RecruitingNCT07213804

Eli Lilly and CompanyOvarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms +1

Start: 2025-10-22End: 2031-08-01Target: 1630Updated: 2026-09-08

Related Papers

FRAmework-01: A two-part phase 3 study of sofetabart mipitecan versus chemotherapy or mirvetuximab soravtansine in platinum-resistant ovarian cancer (PROC), and sofetabart mipitecan plus bevacizumab versus platinum-based chemotherapy plus bevacizumab in platinum-sensitive ovarian cancer (PSOC).

Journal of Clinical Oncology2026-05-28

Abstract 1769: LY4170156, an antibody-drug conjugate targeting folate receptor alpha, exhibits enhanced antitumor activity in combination with standard-of-care therapies in preclinical ovarian cancer models

Cancer Research2026-04-03

A Phase 1/2 Randomized Study to Evaluate the Safety, Tolerability, and Immunogenicity of Nucleoside-Modified Messenger RNA Influenza Vaccines in Healthy Adults

Vaccines2025-04-034 citations